news
CRISPR disruption of NRF2 re-sensitises tumours to chemo
Researchers have shown that using CRISPR to disable the NRF2 gene can restore chemotherapy sensitivity and slow tumour growth.
List view / Grid view
Therapeutics
news
Scripta Therapeutics raises $12m to advance neurodegenerative research
Oxford-based techbio start-up Scripta Therapeutics has announced a $12 million seed funding round helping them to reshape conventional drug discovery.
news
How antibody-drug conjugates are improving gynaecological cancer outcomes
Antibody-drug conjugates (ADCs) are emerging as a breakthrough in the fight against gynaecological cancers, offering targeted treatment for cervical, ovarian and uterine tumours.
article
Circular RNA technology: the future of gene therapy
Pioneering circular RNA could redefine what the future of gene therapy looks like. Erik Digman Wiklund, CEO of Circio, shares how his company’s platform is enhancing gene expression and tackling toxicity challenges through smarter design and scientific collaboration.
news
UK Government announce plans to phase out animal testing for drugs
The UK government have announced a new strategy to phase out animal testing in scientific research, aiming to replace traditional experiments with innovative human-relevant methods such as organ-on-a-chip systems and AI analysis.
news
GLP-1 weight loss drugs may protect against pancreatitis
A new study has found that GLP-1 weight loss drugs do not increase the risk of pancreatitis or heart problems in patients with high triglycerides – and may even help protect against the condition.
news
Protein FSP1 found to help melanoma survive in lymph nodes
New research has discovered a key survival mechanism in metastatic melanoma, revealing that cancer cells spreading to lymph nodes depend on a protein called FSP1 to avoid cell death.
article
Recombinant KLK1: the next step in stroke and preeclampsia treatment
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to restore blood flow, improve endothelial function and address unmet needs in the treatment of stroke and preeclampsia.
article
IL-2 and GLP-1 receptor agonist combination tackles neuroinflammation
Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.
news
CRISPR epigenetic ‘switch’ provides new way to control memory
For the first time, researchers have demonstrated that flipping an epigenetic ‘switch’ in memory cells can directly control whether a memory is expressed or silenced, offering new insights into how memories are stored and potentially altered.
news
Targeting fibroblasts could lead to new heart failure therapies
Long considered structural support cells, a new research study has discovered how fibroblasts actively worsen heart failure by disrupting heart muscle function, which could lead to new therapeutic strategies for heart failure.
news
TRF1 protein identified as potential obesity drug target
Researchers have discovered that removing a telomere-protecting protein, TRF1, makes mice leaner and metabolically healthier without shortening their telomeres, potentially leading to new methods for tackling obesity and age-related diseases.
article
The predictive validity crisis: Pharma’s productivity paradox – Part II
Part II shows that the predictive validity crisis can be solved by rethinking how the industry chooses models, measures outcomes and integrates systems. Success stories from Vertex, Regeneron and AstraZeneca illustrate how aligning biology, measurement and strategy can reverse decades of declining productivity.
news
New compound blend reverses sugar damage to tackle ageing and obesity
Scientists have developed a compound blend that reverses sugar-related cellular damage in mice, which could lead to future therapies to slow ageing and treat metabolic diseases.
news
Pulmonary fibrosis: new drug slows and reverses lung scarring
Researchers have identified a key cellular mechanism that drives pulmonary fibrosis and successfully blocked it in mice, reducing lung scarring.
